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1 Summary 
Lung cancer is one of the most frequent causes for cancer related deaths worldwide and 
commonly treated with radio- and chemotherapy. However, resistant tumor cells often 
complicate therapeutic interventions. We analyzed if Erythropoietin receptor (EPOR) is 
involved in hypoxia-induced resistance to chemo- and radiotherapy in A549 lung cancer cells. 
A CRISPR/Cas engineered EPOR knock out cell line and shRNA EPOR knock down cells 
were used to investigate the response of EPOR deficient cells to radiation and Gemcitabine. 
We showed that EPOR expressing cells responded with resistance to chemo- and radiotherapy 
after hypoxia exposure. This effect disappears in EPOR deficient cells, suggesting that the 
loss of EPOR renders lung cancer cells more susceptible to the treatment, especially to 
irradiation. Radioresistance was independent of DNA damage, repair mechanisms and 
unexpectedly administration of Erythropoietin (EPO) as well as overexpression of 
endogenous EPO was not sufficient to mimic the hypoxia-induced EPOR-dependent 
radioresistance. However, hypoxic preconditioned medium of A549 cancer cells was able to 
protect normoxic A549 wild type cells, which express EPOR. By filtering the hypoxic 
preconditioned medium, we narrowed down the potentially cancer cell protective factor to a 
molecular weight larger than 100 kDa. First attempts to identify this factor suggest the 
possible involvement of extracellular vesicles and EFNB2, a factor thought to be associated 




Lungenkrebs ist einer der häufigsten krebsbedingten Todesursachen weltweit und wird mit 
Chemo- und Radiotherapie behandelt. Oftmals treten jedoch Resistenzen auf, welche die 
Therapien erschweren.  
Wir untersuchten ob und wie der Erythropoietin Rezeptor (EPOR) bei der Resistenz 
gegenüber Chemo- und Radiotherapie in A549 Lungenkrebs Zellen eine Rolle spielt. Mit 
einer CRISPR/Cas EPOR knock out Zelllinie, sowie mit shRNA EPOR knock down Zellen, 
konnten wir zeigen, dass EPOR exprimierende Zellen in Hypoxie eine Resistenz gegenüber 
Chemo- und Radiotherapie entwickeln, während Krebszellen ohne EPOR diese Fähigkeit 
verloren. Wir konnten zeigen, dass bei der EPOR abhängigen Resistenz weder bestrahlungs-
induzierte DNA Schäden noch eine veränderte DNA Reparatur eine Rolle spielten. 
Ausserdem wurde der Schutzeffekt, welcher unter Hypoxie induziert werden kann, durch 
blosse Zugabe von Erythropoietin (EPO), sowohl in Form von rekombinantem humanem 
EPO (rhEPO), als auch die endogene Überproduktion von EPO, unter normoxischen 
Bedingungen nicht erreicht. Allerdings war hypoxisch präkonditioniertes Medium von wild 
Typ und knock out Zellen in der Lage auch normoxische wild Typ Zellen, aber nicht EPOR 
knock out Zellen zu schützen, sogar nach herausfiltrieren aller Substanzen kleiner als 100 kDa 
aus dem präkonditionierten Medium. Erste Versuche zeigten, dass extrazelluläre Vesikel und 






Erythropoietin (EPO) is a glycoprotein mainly produced by the kidney in adults, which is 
essential for survival, differentiation and proliferation of erythroid progenitor cells [1] and 
therefore represents the major member of the group of erythropoiesis stimulation agents 
(ESA). It was originally thought to play an exclusive role for differentiation of red blood 
cells, stimulated by expression of hypoxia-inducible factor (HIF) under hypoxic conditions 
[2]. In addition it is reported to support angiogenesis as well as vasculogenesis [3]. In a 
variety of non-hematopoietic tissues like blood vessels, heart and peripheral nervous system, 
EPO can act as a strong cyto-protective factor [4, 5] [6] [7]. Recombinant human 
erythropoietin is clinically used to correct anemia predominantly in chronic kidney disease to 
restore red blood cell levels, but also to correct anemia in cancer patients where anemia 
correlates with poor patient survival [8, 9]. The only alternative treatment represents a 
repetitive red blood cell transfusion, which harbors the risk of infection, iron overload and 
thrombotic events [10]. Also cyclic hypoxia between treatments can occur, which was shown 
to be even more detrimental than acute hypoxia for tumor behavior [11]. If and how EPO 
impacts on tumors is still – even after decades of research – controversially discussed and 
many publications about the impact of recombinant human EPO treatment for cancer patients 
as well as for the impact in in vitro experiments seem to contradict each other. Several clinical 
studies could show an poor prognostic outcome for cancer patients undergoing rhEPO 
treatment [9], as well as growth response in in vitro and in vivo experiments [12] [13] [14]. 
Since the discovery of the erythropoietin receptor (EPOR) gene expression in various tumor 
cell lines and carcinomas [15], concerns about EPO-EPOR dependent survival and tumor 
progression were raised [16] [17]. It was discussed that rhEPO could influence cancer cells 
either by stimulating tumor angiogenesis by interacting with EPOR present on endothelial 
cells or direct via EPO/EPOR signaling on cancer cells, possibly inducing tumor proliferation, 
metastasis and resistance to therapeutic approaches [18] [1]. However, several other studies 
failed to demonstrate proliferative effects of exogenous rhEPO treatment in in vitro 
experiments as well as for prognostic outcome in patients [19] [20] [21]. Swift et al. found 
that even if EPOR was detectable on mRNA level in many cancer cell lines, no functional 
EPOR could be found in nearly all of the tested cell lines. In addition they could find no 
upregulation of EPOR in hypoxia, nor an activation of EPOR downstream pathways as 
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reaction to rhEPO administration [22]. These reports have led to precaution in prescribing 
rhEPO to anemic cancer patients, especially because mechanisms behind EPO/EPOR 
communication in cancer cells is not yet fully understood. 
 
Because lung cancer is the leading cause of cancer death among both men and women, with 
80% to 85% categorized as non-small cell lung cancer (NSCLC) [23][22] it represents an 
important subject for cancer related studies. NSCLC have been also reported to express 
EPOR [24] and it was shown that EPOR expression in NSCLC, results in decreased 
sensitivity to cisplantin in response to EPO stimulation [25]. Recently, it has been reported, 
that the co-expression of endogenous EPO-EPOR is a negative prognostic factor for early-
stage non-small lung cancer (NSCLC) [26], and that co-expression is positively associated 
with poor survival of NSCLC patients [27]. In contrast Doleschel et. al could show in their 
study from 2015 that EPO administration in fact lead to a beneficial reaction to carboplantin, 
due to enhanced tumor vascularization and perfusion [24]. The important function of EPOR 
has been also shown in other types of cancer including glioma, where the loss of EPOR 
reduces cancer cell proliferation [28] and increases cancer cell response to irradiation and 
temozolomide [29]. Particularly hypoxic environment seems be an essential factor for 
resistance of cancer cells to radio and chemotherapy [30] [31]. EPO expression is induced 
under hypoxic conditions via hypoxia-inducible factor 2, which is a heterodimeric 
transcription factor consisting of a stably expressed β and an oxygen-regulated α-subunit. In 
conditions of low oxygen, HIF2-α escapes proteasomic degradation, followed by nuclear 
translocation and heterodimerization, finally leading to activation of target genes with EPO 
being one of them [32]. In this study we analyzed the role of EPOR in A549 lung cancer cells 
– especially in the context of hypoxia-induced resistance to chemo- and radiotherapy. We 
utilize shRNA knock down cells and the recently developed CRISPR/Cas technology to 
establish EPOR deficient A549 cells and explored their response to Gemcitabine, a first line 
lung cancer treatment as well as radiation, which is frequently used for lung cancer patients 







4 Materials and Methods 
4.1 Cell culture 
 
A549 adenocarcinomic human alveolar basal epithelial cells, used in this study were grown 
and maintained in Dulbecco’s Minimum Essential Medium (MEM) with Earle’s Salts 
supplemented with 2ml L-glutamine, 10% fetal bovine serum (heat inactivated), 20 mM 
HEPES buffer solution and Penicillin/Streptomycin. Cells were split twice a week in a ratio of 
1/10 after washing cells with PBS and incubating them with Trypsin (Gibco by Life 
Technologies) for 2-3 minutes. A549 wild type cells, shRNA scrambled cells and shRNA 
EPO receptor knock down cells where a generous gift from Julian Aragonez [35] (Fig. 1A). 
Cells were kept at 37° C in normoxia (21% O2 and 5% CO2) Revco (Thermo Scientific) or 
hypoxia at 37° C in normoxia (1% O2 and 5% CO2)  in Hera cell 240 incubator (Heraeus). 
 
4.2 CRISPR/Cas9 EPOR Knock Out Generation 
 
CRISPR/Cas9 knock out generation was done in cooperation with Julia Armbruster. To 
obtain EPOR KO cells with genetically identical wild type control, monoclonal colonies were 
generated by seeding single cells into 96 well plates growing them in MEM with 20% FCS. 
After expansion of monoclonal colonies protein was isolated analyzed for EPOR expression 
levels and clone number 9 was selected for CRISPR/Cas knock out, due to its high EPOR 
expression level. Two 20-nt long sgRNAs (Table 1) were designed using the CRISPR Design 
Tool [36] to follow the conventional (double strand break) and the Nickase approach of the 
CRISPR/Cas9 protocol [37].To briefly describe the process: pSpCas9(BB)-2A-Puro 
(PX459)(conventional double strand break) and pSpCas9n(BB)-2A-Puro V2.0 (PX462) 
(Nickase) were a gift from Feng Zhang (Addgene plasmid # 62988 # 62987) [38]. The vectors 
express Cas9 wild type (px459) or Cas9n (Nickase) (px462) of S.pyogenes and include the 
scaffold of sgRNA, as well as a Bbs1 cutting side to allow integration of sgRNA. 
Additionally, the vectors have an Ampicillin and a Puromycin resistance cassette allowing 
later selection of successfully transfected cells. The sgRNA 2 was cloned into the px459 
Vector and, additionally, both sgRNA1 and sgRNA2 were cloned into two independent px462 
vectors, expressing the mutated Cas9 enzyme with nickase activity (CRISPR/Cas9n) to guide 
Cas9 to target side. A549 cells were transfected with Lipofectamine 2000 according to the 
suppliers protocol [39] on 6-well plates using 2500 ηg plasmid DNA per well and transfected 
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cells were selected with 1 μg/ml Puromycin (Sigma Aldrich). After selection monoclonal 
clones were generated as described above and genomic DNA was isolated from cell pellets 
with a homogenization buffer (50mM KCL, 10mM Tris-HCL (pH 8.3), 0.01mg/ml Gelatine, 
0.045% Nonidet P-40, 0.045% Tween 20) with 50 μg/ml proteinase K (New England Biolabs) 
over night at 55° C. After heat inactivation of proteinase K at 95° C for 10 minutes, cells were 
centrifuged 5 min at 14860 rpm and 80 μl of the supernatant was transferred into a fresh tube. 
Genomic human EPOR DNA was amplified with a nested PCR using Primers shown in Table 
1. PCR products were purified using QIAquick PCR purification kit (QIAGEN), cloned into 
pGEM-T vectors (Promega) and vectors were transformed into NEB 5-α competent E.coli 
(New England Biolaps) following the High Efficiency Transformation Protocol ([40] New 
England Biolaps). Plasmid DNA was isolated using QIAprep Spin Miniprep Kit (QIAGEN) 
and sequenced by Microsynth (Fig. 1B). The DNA Sequences were analyzed using NCBI and 
resulting protein sequences were determined using the Expasy Translation tool (Fig. 1C)[41]. 
A549 EPOR knock out was validated via Western Blotting (Fig. 1D). 
 
 
Table 1 Sequences of sgRNAs and EPOR primers to identify genetic modifications. 
20 nt sgRNA Sequence 
Guide Sequence 1 (sgRNA1) 1_fwd: 5’ CACCgATGATACAGCCCCCGCCACG 3’ 
1_rev:           3’ cTACTATGTCGGGGGCGGTGCCAAA 5’ 
 
Guide Sequence 2 (sgRNA2) 2_fwd: 5’ CACCgACCACCTCGGGGCGTCCCTC 3’ 
2_rev:           3’ cTGGTGGAGCCCCGCAGGGAGCAAA 5’ 
 
EPOR Primer  





PCR 1_fwd : TCGGGGATCTGCCACTTAGA 
PCR 1_rev :  CACCAAGTCAGCCCCCTTAG 
2. PCR 
 
PCR 2_fwd: GACCCAGCTGTGGACTGTG 




Fig.1 Establishing cell lines with different EPOR expression levels. A: EPOR expression levels in shRNA 
transfected monoclonal cells were confirmed via Western Blotting. Picture shows EPOR protein expression 
levels for 3 shSCR (ctrl) and 3 shEPOR (EPOR knock down). Tubulin was used as loading control. B: Wild type 
DNA Sequence of human EPOR gene is shown, followed by the modified 2 alleles of our CRISPR/Cas9 A549 
EPOR knock out clone. Allele one shows a modification of 9 deleted base pairs (bp) with 38 inserted base pairs 
resulting in a prolongation of allele one for 29 bp (bold characters). Second allele was modified with 5 bp 
deletion and a 215 bp insertion resulting in a total prolongation of the allele for 210 bp (bold characters). C: 
Shows wild type human EPOR protein sequence with highlighted EPO-binding domain (bold). Translation of 
modified DNA sequences of the CRISPR/Cas knock out from panel B into protein sequences, indicates a loss of 
EPO binding domain (first 173 amino acids) on both alleles confirming a functional EPOR knock out. D: 
Verification of functional EPOR knock out on Protein level using Western Blot analysis. Beta actin was used as 
loading control. 
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4.3 Clonogenic Assay 
 
Clonogenic Assays were performed on 6-well plates (for experiments with Gemcitabine 
treatment and EPO overexpression) in 2 ml 20% FCS MEM medium per well and cells were 
kept at normoxia (21% O2) for 24 medium. 250 cells/well were seeded in three to four 
independent experiments (n) and each experiment was run in triplicates. For all other 
experiments, cells were seeded in duplicates for each individual experiment (n) in 25 cm2 
venti cap flasks (Corning, 430168) with 300 cells/flasks in 5ml 20% FCS MEM medium. 24 
hours after seeding, cells were treated as described below and 48 hours after seeding, cells 
were exposed to a single dosage radiation (0,1,2,3 Gy) with a 6 megavolt (MV) linear 
accelerator (Clinac iX, Varian, Palo Alto, CA, USA) using photons. After radiation flasks or 
plates where placed back into normoxic or hypoxic incubators. All clonogenic Assays were 
fixed and stained after 7-10 days over night with a solution containing 0.5% Crystal-Violet 
and 0.6% glutaraldehyde. All colonies >50 cells were counted. All data was normalized to 
untreated control and results are shown in %. 
Treatments: 
a) Normoxic/ Hypoxic Clonogenic Assays 
After seeding cells and incubating them for 24 hours in normoxia, flasks where either 
transferred into hypoxia or remained in normoxia. Another 24 hours later caps of 
hypoxic flasks where closed for irradiation outside of hypoxic incubators and 
reopened before being placed in hypoxia again.  
 
b) Gemcitabine – a Chemotherapeutic often used as Treatment for NSCLC 
Gemcitabine was added after 24 hours of incubation in normoxia and cells were either 
placed back into normoxia or transferred into hypoxic incubators.  
 
c) rhEPO Treatment 
24 hours after seeding, medium was removed and replaced with 5 ml of fresh 20% 
FCS MEM medium supplemented with 5 U/ml rhuEpo (Recormon; Roche).  
 
d) Endogenous EPO Overexpression 
A549 WT cells were seeded at 50% confluence in 6-well Plates and were transfected 
with LipofectamineTM 3000 Transfection Reagent (Invitrogen) with 3.75 μl 
Lipofectamine 3000 per well and 2.5 μg total vector DNA/well, as recommended in 
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Lipofectamine 3000 Protocol [42]. PLenti6.3-hEpo, a gift from Juan Melero-Martin 
(Addgene plasmids # 50436), was used for endogenous EPO overexpression and an 
empty vector expressing mCherry (pmCherry-N1, Clontech, Cat. 632523) served as 
negative control as well as to verify transfection efficiency by immunofluorescence. 
Medium was replaced 24 hours after transfection and, after another 24 hours, 
collected. After centrifugation to remove cell debris, medium was supplemented with 
10% and 2 ml were put on cells of a clonogenic assay. 
 
e) WT and EPOR KO Preconditioned Medium 
EPOR WT and KO cells were seeded incubated in 10 cm plates for 24 hours in 10% 
FCS Medium. Cells were then transferred to hypoxia or remained in normoxia for 
another 24 hours. Finally, medium was collected and pooled from all plates for each 
condition. PC medium was centrifuged to remove cell debris, filled into fresh tube 
and substituted with another 10% FCS. Afterwards, cells of clonogenic assays were 
incubated with 5 ml of PC Medium for 24 hours. 
 
f) Centrifugal Filtration 
Preconditioned (PC) medium was centrifuged to remove cellular debris, filled into 
fresh tubes and divided in two groups. One half of the medium remained at room 
temperature as a control to the further processed second half of PC medium. For 
further processing, PC medium was centrifuged in Centricon Plus-70 Centrifugal 
Filter Devices (Merck/Millipore; 3kDa, 30kDa, 100kDa) for 50 min at 21° C and 
3500 x g to obtain concentrated medium and to remove molecules smaller than the 
indicated filter size. To recover the condensed PC medium, columns were inverted 
and centrifuged for 2 min at 1000 x g and the recovered PC medium was diluted in 40 
ml fresh MEM medium without FCS. The process was repeated twice to ensure 
complete removal of all molecules smaller than the indicated filter size. At the final 
step, the condensed and filtered medium was diluted in fresh 20% FCS containing 
MEM medium and cells of clonogenic assays were incubated with 5 ml processed 
medium or unprocessed PC control medium. 
 
g) Microvesicle Isolation (>100nm) 
After 24 medium incubation 10% FCS preconditioned Medium (PC) of confluent 
hypoxic or normoxic 10 cm plates, was collected. Preconditioned (PC) Medium was 
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centrifuged to remove cell debris, filled into fresh tubes and divided in two groups. 
One half of the medium remained at room temperature as a control to the further 
processed second half of PC medium. For isolation of microvesicles > 100 nm in 
diameter from PC medium, different centrifugation steps where performed according 
to the following protocol [43]. The vesicle pellet was then taken up in original 
volume of fresh 20% FCS medium and cells of clonogenic assays were incubated 
with 5 ml processed medium or unprocessed control medium. 
  
4.4 γH2AX – as Marker for DNA-damage 
 
Round cover slips were placed in 24-well plates and sterilized with ethanol. After drying up, 
cells were seeded in these wells in 500 μl 10% FCS MEM medium (20000 cells/well). After 
24 hours incubation in normoxia, cells were transferred into hypoxia or remained in 
normoxia. Another 24 hours later cells were either irradiated (1 and 3 Gy) or remained 
untreated. 0,5 or 24 hours post irradiation cells were washed with 1 x PBS and fixed with 4% 
Formalin for 15 minutes. After washing three times for 5 minutes in PBS, fixed cells were 
incubated with 0.5% T X-100 (T8787, Sigma Aldrich in PBS) for 30 minutes. After washing 
with PBS, cells were blocked for 1 hour with 3% BSA (A7906100G, Sigma Aldrich in PBS). 
γH2AX-antibody (γH2AX Ser139, Millipore, Temecula, CA, USA) was diluted 1:200 in 1% 
BSA and cells were incubated for 2 hours with the antibody solution. Afterwards, cells were 
washed 3 times with 1x PBS and exposed to the secondary antibody dilution (Alexa 488 
donkey anti mouse (green) diluted 1:250 in PBS) for 1 hour. Finally, fixed cells were 
incubated with DAPI (blue, diluted 1:1000 in PBS) for 10 minutes, followed by 2 washing 
steps with PBS. The cover slips were mounted on one drop of Dako fluorescent mounting 
medium on glass slides and after short drying time, sealed with nail polish. Zeiss Imager 72 
fluorescent microscope coupled to an 8-bit CCD camera was used to analyze slides. With 40x 
magnification, 2-4 visual fields pictures where taken until a minimum of 100 cells per 
condition per passage were captured (n=3-4) and DAPI-stained nuclei as well as γH2AX foci 





4.5 RNA Extraction, cDNA Synthesis and Real-time PCR 
 
RNA was isolated using the ReliaPrep RNA Cell Miniprep System following the supplier 
instructions (Promega) and quantified using Nanodrop (Thermo Fisher). Isolated RNA was 
transformed to cDNA by using 10 μl of RNA (100 ng/ μl) and annealing it with 1 μl Oligo dT 
(10 μM; Promega) for 5 minutes at 65° C followed by rapid cooling on ice. After 15 μl of 
Master mix (5.57 μl H2O, 5 μl 5x Reaction Buffer for RT (Thermo Fischer), 2.5 dNTPs (15 
mM each, Thermo scientific), 1 μl RNasin (Promega), 0.25 μl 100x BSA (New England 
Biolaps), 0.5 μl Revert Aid Reverse Transcriptase (Thermo scientific)) was added to the 
RNA, samples were incubated at 42° C for 2 hours, followed by inactivation of the reaction at 
65° C for 10 minutes. 175 μl H2O were added to obtain a final cDNA concentration of 5 
ng/μl. Primers were designed by Primer3 software [44] [45] and purchased at Microsynth. 
Used primers are shown in table 2. Master mix was prepared on ice containing 5 μl 
LightCycler 480 SYBR Green I Master (Roche Applied Science, Cat. 04707516001), 1 μl 
Primer forward (10 μM), 1 μl Primer reverse (10 μM) (Microsynth) and 1 μl H2O per sample. 
Samples were run in duplicates and 2 μl cDNA (5ng/ μl) was added to 8 μl master mix per 
well, in MicroAmp Fast Optical 96-Well Reaction Plate (Applied Biosystems by life 
technologies) on ice. Plate was sealed with Optical Adhesive Covers (Applied Biosystems by 
Life Technologies), and centrifuged for 2-3 minutes at 2500 x g, before being placed in 
Thermocycler ABI7500 Fast (Applied Biosystems) to run Real-time PCR. Amplification 
profile was as follows: 50° C for 2 min; 95° C for 10 min; 40 cycles at 95° C a 30 sec and 60° 
C for 40 sec, followed by melt curve analysis. Fold changes were determined by delta-delta 
Ct method and normalized to beta-Actin. 
 
Table 2 Primer sequences for genes that were analyzed with Real-time PCR (SYBR 
green method). 
Target Gene Primer Pair 
ACTB 
NM_001101.2 
Fwd: 5’ CTGGAACGGTGAAGGTGACA 3’ 
Rev: 5’ AAGGGACTTCCTGTAACAACGCA 3’ 
EPO 
NM_000799.2 
Fwd: 5’ ATGTGGATAAAGCCGTCAGT 3’ 
Rev: 5’ AGTGATTGTTCGGAGTGGAG 3’ 
PTGES 
NM_004878.4 
Fwd: 5’ GGATGCCCTGAGACACGGAG 3’ 
Rev: 5’ CAGAAAGGAGTAGACGAAGCCCA 3’ 
MVP 
NM_005115.4 
Fwd: 5’ TCCAGAGGGTCCAGAAGGTCCGAGAGC 3’ 
Rev: 5’ GCCCCATCCCCAGCAGCCCAAAGG  3’ 
EphB4 
NM_004444.4 
Fwd: 5’ ACAAACACGGACAGTATCTCATC 3’ 
Rev: 5’ GCACCAATCACCTCTTCAATCT 3’ 
EFNB2 
NM_004093.3 
Fwd: 5’ CTCAACTGTGCCAAACCAGA 3’ 
Rev: 5’ GCCCTCCAAAGACCCATT 3’ 
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4.6 Western Blot 
 
Cells were lysed with RIPA Buffer (20 mM Tris, 150 mM Sodium chloride, 1% Triton X-
100, 1% Na-deoxycholate, 0,1% SDS) and the Pierce Bicinchoninic Acid (BCA) Protein 
Assay was used for determination of protein concentration. Proteins were separated by SDS-
PAGE and transferred to Nitrocellulose Blotting Membrane (GE Healthcare Life Science). 
After blocking the membrane in 5% milk in TBST (Rapidlait, Migros, Switzerland), the 
following primary Antibodies were diluted in 5% milk: rat anti-EPOR 1:200 (GM1201; 
Adlevon), rabbit anti-alpha Tubulin 1:1000 (ab4074; Abcam), mouse anti-ACTB 1:5000 
(Sigma Aldrich). Blots were exposed to HRP conjugated secondary antibodies diluted in 5% 
milk in TBST: goat anti-rat 1:5000 (sc-2032; Santa Cruz), donkey-anti-rabbit 1:5000 
(NA934V; Amersham), goat-anti-mouse 1:5000 (Santa Cruz sc-2031). Bands were visualized 
using Super Signal West Femto Maximum Sensitivity Substrate (Thermo Scientifc) and 
recorded with FUJIFILM Intelligent Darkbox Las-300. 
 
5 Results 
5.1 The Loss of EPOR Sensitizes A549 Lung Cancer Cells towards 
Gemcitabine 
 
Targeting EPOR in glioblastoma cells has been shown to increase the response to 
chemotherapeutics [29]. To study the impact of EPOR on chemotherapy in lung cancer, A549 
cells with reduced (shRNA; knock down) and ablated (CRIPSR/Cas; knock out) EPOR 
expression levels were used. With exposure to increasing concentrations of Gemcitabine, the 
number of formed colonies in a clonogenic assay, as a measure of survival, declined in a 
dose-dependent manner (Fig. 2 A,B,D,E). No statistically significant difference in colony 
formation after Gemcitabine treatment between scrambled (shSCR) and knock down 
(shEPOR) clones under normoxic conditions was observed, although the results indicate a 
clear trend of higher gemcitabine sensitivity in shEPOR knock down clones (Fig. 2A). 
However, under hypoxic conditions shSCR clones are better protected from gemcitabine 
treatment and formed more colonies compared than shEPOR knock down clones (Fig. 2B). 
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Finally, A549 shSCR cells display a moderate but statistically not significant hypoxia-
induced resistance to Gemcitabine treatment (Fig. 2C)1. 
In addition to shRNA mediated EPOR knock down, a CRISPR/Cas mediated EPOR knock 
out clone (EPOR KO) was generated to confirm these findings. In line with the shEPOR 
knock down experiments (Fig. 2A-C), functional ablation of EPOR increased the 
Gemcitabine sensitivity under hypoxia but not under normoxic conditions (Fig. 2D, E). As 
observed in shRNA knock down experiments, the exposure to hypoxia induced a moderate 
yet not significant resistance to Gemcitabine in EPOR WT clones but not in EPOR KO clones 
(Fig. 2F). These data suggest that the loss of EPOR sensitizes A549 lung cancer cells towards 




Fig. 2 EPOR dependent hypoxia-inducible resistance to Gemcitabine in A549 lung cancer cells 
The role of EPOR in Gemcitabine efficacy in A549 lung cancer cells was analyzed by 3 individual shSCR control (light grey 
bars) and 3 shEPOR knock down (black bars) clones as well as by EPOR knock out (KO; CRISPR)(dark grey bars) and wild 
type (WT; white bars) clones. 
A,B,C,D,E,F: Colony formation was analyzed by clonogenic assay under normoxic (21% O2) and hypoxic (1% O2) 
conditions with increasing concentrations of Gemcitabine treatment. Results are shown as colony formation in % of untreated 
controls (Y-axis). Cells were exposed to Gemcitabine 24 h post seeding and remained in normoxia or were transferred into 
hypoxia. Colonies were fixed, stained and quantified after 7-10 days. A,B: The response to increasing Gemcitabine 
concentrations (X-axis) of shSCR  and shEPOR cells under normoxic (A) and hypoxic (B) conditions was analyzed. Data 
show significant differences between shSCR and shEPOR clones in hypoxia, but not in normoxia. C: Comparison of 
normoxia (horizontal stripes and hypoxia (vertical striped bars) exposed shSCR and shEPOR clones after treatment with 2.5 
ng/ml Gemcitabine. Shown is colony formation (Y-axis) normalized to untreated shSCR and shEPOR knock down cells in 
%. D,E: Response to increasing Gemcitabine concentrations of WT (white bars) and EPOR knock out clones (dark grey bars) 
under normoxic (D) and hypoxic (E) conditions. F: Colony formation under normoxic (horizontal striped bars) and hypoxic 
(vertical striped bars) conditions of WT and EPOR KO cells after treatment with 2.5 ng/ml Gemcitabine. A Students t-test 
was performed for statistics. (Mean ± SD; n=3-4; *p<0.05;). 
                                                        
1 Please note: Results of figure 2 A-C were generated by Julia Armbruster as part of her master thesis [46] 
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5.2 Hypoxia-inducible Resistance to Radiotherapy is EPOR Dependent 
 
It has been shown before that shEPOR knock down in U87 cells can increase the efficacy of 
irradiation, compared to shSCR (control) U87 cells [29]. 
To analyze how the expression of EPOR may impact the radiation efficacy in lung cancer, 
A549 lung cancer cells were exposed to different intensities of single radiation dosages (1; 2; 
3 Gy) and cell survival was monitored with a clonogenic assay. With increasing dosages, the 
number of formed colonies declined in a dose-dependent manner. Comparing shSCR with 
shEPOR (Fig. 3A) as well as WT with EPOR KO in normoxia (Fig. 3B) reveals no 
differences between EPOR expressing and EPOR deficient groups in colony formation 
independent of the utilized dosage. In contrast, under hypoxic conditions shSCR cells form 
more colonies compared to shEPOR (Fig. 3C) reaching a statistical significance at a dosage of 
2 Gy, suggesting that hypoxic exposure protects EPOR expressing cells but not EPOR 
deficient cells. Similarly, hypoxic EPOR KO cells show significantly less colonies after 
irradiation with 1 and 3 Gy than their respective WT controls (Fig. 3D). A different 
representation of shown data in Figure 3 E and F clearly demonstrates that 3 Gy exposed 
shSCR control (Fig. 3E) as well as EPOR WT cells (Fig. 3F) display a better survival of 
colonies under hypoxic conditions compared normoxia. In contrast, clones with reduced 
(shEPOR) (Fig. 3E) or ablated (EPOR KO) (Fig. 3F) EPOR gene expression levels fail to 
show the hypoxia-induced resistance to irradiation. These data support our hypothesis of 
EPOR being involved into hypoxia-induced resistance to radiation.  
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Fig. 3 EPOR dependent hypoxia-inducible resistance to radiotherapy in A549 lung cancer cells 
Colony formation was analyzed after irradiation with clonogenic assay. Results where normalized to non-irradiated controls 
and are shown in % (Y-axis). Cells were seeded in normoxia (21% O2) and either remained in normoxia or were transferred 
into hypoxia (1% O2) 24 h prior to radiation with increasing radiation dosages. Colonies where fixed, stained and quantified 
after 7-10 days. A,B: Shown is the average response in normoxia of three individual shSCR control (light grey bars) and 
shEPOR knock down clones (black bars) (A) as well as of the WT (white bars) and EPOR KO (dark grey bars) clone (B) to 
increasing dosages of radiation (X-axis). C,D: Shown is the average response in hypoxia of three individual shSCR control 
and shEPOR knock down clones  (C) as well as of the WT and EPOR KO clone (D) to increasing dosages of radiation (X-
axis).  E,F: Comparison of normoxia (horizontal striped bars) and hypoxia (vertical striped bars) exposed shSCR and shEpoR 
clones after irradiation (3 Gy) (E), as well as of WT and EPOR clones (F). A Students t-test was performed for statistics. 
(Mean ± SD; n=3; *p<0.05; **p<0.01) 
 
5.3 EPOR-dependent Radioresistance does not Depend on Protection from 
DNA-damage or Repair of DNA-damage 
 
It is known that radioresistance in hypoxia is associated with decreased DNA-damage due to a 
decreased fixation of potentially lethal DNA double stand breaks, as well as activation of 
additional DNA-repair pathways [47].  
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To explore if EPOR dependent radioresistance involves protection from DNA damage or 
DNA repair mechanisms, γH2AX was used as a measure of DNA-damage (Fig. 4A and B). 
Immunofluorescence staining of γH2AX under normoxic conditions (Fig. 4C) suggests that 
DNA damage in non-irradiated EPOR WT and KO cells (baseline) is comparable. Radiation 
with 1 Gy leads to a significantly higher number of γH2AX foci/cell after 30 min compared to 
baseline, but no difference between EPOR WT and KO cells was observed (Fig. 4C). 
Similarly, hypoxia exposed cells display neither differences in non-exposed cells (baseline) 
nor 30 minutes after irradiation (Fig. 4D). Despite the identical γH2AX response of WT and 
KO clones, we further observed, surprisingly, no significant difference between normoxic and 
hypoxic incubated WT cells (Fig. 4E) as well as EPOR KO cells (4F), suggesting that 
hypoxia-induced radioresistance might be independent of differences in DNA damage in our 
experimental setup. Whereas γH2AX quantification early after irradiation (e.g. 30 minutes 
post irradiation) may reflect the intensity of DNA damage, γH2AX at a later second time 
point (e.g. 24 h) represents a mixture of DNA damage and DNA repair. To assess if DNA 
repair mechanisms might be involved in EPOR-dependent radioresistance, γH2AX was 
quantified by immunostaining 24 h after radiation in normoxia and hypoxia exposed EPOR 
WT and KO cells (Fig. 4 G, H). However, 24 hours after radiation with a dosage of 3 Gy, no 
differences in DNA-damage between EPOR KO and WT cells in response to radiation under 
normoxia (Fig. 4G) or hypoxia (Fig. 4H) were detected. Furthermore, the γH2AX baseline 
value of EPOR WT and KO clones and under normoxic as well as hypoxic conditions was 
identical in non-irradiated cells (Fig. 4G,H). Finally, no difference in DNA-damage of each 
clone can be seen in between normoxia or hypoxia neither for WT cells (Fig. 4I) nor EPOR 
KO cells (Fig. 4 J), suggesting that hypoxia-induced radioresistance might be also 
independent of DNA repair mechanisms in our experiments. 
In conclusion, these data show that irradiation induces DNA damage in A549 cancer cells, but 
indicate that EPOR-dependent radioresistance may not involve DNA damage or DNA repair 
mechanisms. Moreover, because γH2AX is not altered by hypoxia exposure in irradiated and 
non-irradiated EPOR WT cells it appears that hypoxia-induced radioresistance may not 





Fig. 4 DNA Damage and repair mechanisms are not controlled by EPOR under both, normoxic and hypoxic conditions  
DNA Damage of A549 WT and EPOR KO clones after irradiation was visualized and quantified using a γH2AX Antibody 
(Anti-phospho-Histone H2AX (Ser139) Antibody, (#05-636), Milipore). Cells were seeded under normoxic conditions (21% 
O2) and exposed to either normoxia or hypoxia (1% O2) 24 h prior to radiation. After fixation, cells where stained for γ-
H2AX (green) and counterstained with DAPI (blue). At least 100 cells were counted and average γH2AX-foci per nucleus 
where calculated. A,B: Representative pictures of γH2AX staining 0.5 h after radiation dosage of 1 Gy (A) or 24 h after 
irradiation with 3 Gy (B) C,D: Shown is the average number of γH2AX-foci/cell of normoxic (B) and hypoxic (C) EPOR 
KO and WT cells without irradiation (0 Gy) as well as 30 min after radiation with 1 Gy. E,F: Alternative representation of 
the data from C and D to visualize the impact of hypoxia exposure on DNA damage. Average number of γH2AX-foci/cell in 
WT (E) and EPOR KO (F) cells to contrast normoxia (horizontal striped bars) with hypoxia (vertical striped bar) G,H: 
Shown is the average number of γH2AX-foci/cell of normoxic (C) and hypoxic (D) EPOR KO and WT cells without 
irradiation (0 Gy) as well as 24 h after radiation with 3 Gy. I,J: Alternative representation of the data from G and H to 
visualize the impact of hypoxia exposure on DNA damage/repair. Average number of γH2AX-foci/cell in WT (I) and EPOR 
KO (J) cells to contrast normoxia (horizontal striped bars) with hypoxia (vertical striped bar) No significant differences 
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between WT and EPOR KO could be seen at either time points or conditions. A Students t-test was performed for statistics. 
(Mean ± SD; n=3-4) 
 
5.4 Hypoxia Preconditioned Medium Protects A549 Lung Cancer Cells in 
a EPOR-dependent Fashion  
 
The data above indicate that hypoxia-induced radioresistance requires the expression of 
EPOR in A549 cancer cells suggesting that cancer cell-specific EPO expression, which might 
be induced during hypoxia exposure, is responsible for the protective effect. To determine if 
hypoxia-inducible protection is mediated via auto- or paracrine pathways, experiments with 
normoxia and hypoxia preconditioned medium were performed. Medium of hypoxia but not 
normoxia exposed A549 EPOR WT cells protected A549 EPOR WT but not EPOR KO cells 
in a colony forming assay after irradiation with 3 Gy (Fig. 5 A), suggesting that the 
incubation of colony forming cells with hypoxia preconditioned medium is sufficient to 
mediate radioresistance without any need to directly expose these cells to hypoxia. In other 
words, hypoxia preconditioning causes the release of a factor into the medium protecting cells 
in a paracrine way, which have been kept in normoxia during the whole experiment. 
Furthermore, hypoxia preconditioned medium of A549 EPOR KO cells is also able to protect 
A549 EPOR WT but not KO colonies (Fig. 5B) indicating that that the release of such a 
factor is independent of EPOR but requires EPOR to confer radioresistance. EPO is the 
classical ligand for the EPO receptor and the most plausible candidate for EPOR-dependent 
radioresistance in A549 cells. However, EPO mRNA expression was hardly expressed in 
normoxic (CT >35) and not up regulated in hypoxia-exposed A549 cancer cells (data not 
shown). Furthermore, normoxic A549 EPOR WT cells, which become radioresistant when 
exposed to hypoxia-preconditioned medium, were not protected from 3 Gy irradiation after 
the treatment with a high dose of rhEPO (5 U/ml) (Fig. 5C). The activity of rhEPO has been 
verified in mice where it induced hematopoiesis (data not shown). To assess if the synthetic 
origin of rhEPO may cause this ineffectiveness, cells were also transfected with an EPO 
overexpressing Vector to analyze the impact of preconditioned medium with endogenously 
produced EPO on radioresistance of A549 EPOR WT cells (Fig. 5D). Compared to a 
mCherry control vector, the EPO expression vector induced EPO mRNA expression levels 
>4000 fold (average n=3) (Fig. 5E). However, even the strong EPO overexpression caused no 
protection of A549 EPOR WT cells after 3 Gy irradiation, suggesting that EPO itself is not 
required to mediate EPOR-dependent radioresistance. 
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Fig. 5 Hypoxia-induced radioresistance depends on EPOR but might be EPO independent 
Colony formation was analyzed after a single dose of radiation (3 Gy) via clonogenic assay. Data were normalized to non-
irradiated controls and are shown in % (Y-axis). A,B: Medium was taken from confluent WT (A) or EPOR KO cells (B) 
under normoxic (21% O2; white bars) or hypoxic (1% O2; black bars) conditions to obtain preconditioned medium (PC). PC 
medium of WT (A) or EPOR KO cells (B) was added to WT and EPOR KO clonogenic assays one day prior to irradiation 
treatment (3 Gy) and colony formation was analyzed 7-10 days later. Hypoxic PC medium (black bars) of WT cells (A) and 
EPOR KO cells (B) results in an increased number of WT colonies but not EPOR KO colonies, when compared to normoxic 
PC medium. C: 24 h prior to irradiation either fresh medium (white bars) or fresh medium supplemented with 5 U/ml rhEPO 
(black bars) was added to cells and colony formation was analyzed 7-10 days later. Neither WT not EPOR KO cells display a 
difference after EPO treatment. D: 24 h prior to irradiation either medium of mCherry transfected WT cells (white bars) or of 
EPO overexpressing transfected WT cells (black bars) was added to cells and colony formation was analyzed 7-10 days later. 
E: Semi-quantitative analysis of mRNA by SYBR Green Real-time PCR was used to analyze EPO gene expression of 
transfected A549 WT cells (X-axis). White bars represent mCherry-transfected cells, whereas black bars represent cells 
transfected with an EPO overexpressing Vector (PLenti6.3-hEpo).Target gene expression was normalized to β-Actin and is 
shown as fold changes (Y-axis) (delta-delta Ct method). A Students t-test was performed for statistics. (Mean ± SD; n=3-4;  




5.5 Identification of Potential Factors Stimulating EPOR-mediated 
Radioresistance 
 
Since hypoxia-induced radioresistance occurred to be not solely based on EPO, additional 
factors with cyto-protective properties and a history of association with the EPO/EPOR 
signaling pathway were considered. Possible candidates, either as alternative ligands or as co-
stimulating (together with EPO) factors, were analyzed by Real-time PCR. Prostaglandin E 
Synthase (PTGES) is a novel HIF-inducible gene [48] regulating Prostaglandin E2 (PGE2) 
biosynthesis, which itself is reported to enhance EPO-mediated STAT5 transcriptional 
activity [49]. Therefore, we quantified Prostaglandin E Synthase expression levels (Fig. 6A). 
However, no significant differences between WT and EPOR KO clone or between normoxia 
and hypoxia were observed, although there is a clear trend for PTGES to be downregulated in 
hypoxia. However, hypoxia preconditioned medium most likely requires an upregulated and 
released factor. Consequently, we did not further analyze PTGES.  
The Major vault Protein (MVP) in humans also called “drug-resistance related protein” (LRP) 
is a 110 kDa in size, which is known to stand in relation with drug resistance in cancer cells 
[50] and interacts with pathways also interacting with EPO. Even though WT cells show a 
higher expression of MVP then EPOR KO cells, again we found a downregulation in hypoxia 
for both cell lines (Fig. 6B), excluding MVP as a potential candidate. 
Recently it has been shown that EPO acts as an alternative ligand for the Ephrin B4 receptor 
(EphB4)[51]. However, it is not clear if EphrinB2 (EFNB2), the classical ligand for EphB4, is 
also able to bind and activate EPOR. The expression pattern of EphB4 (Fig. 6C) and EFNB2 
(Fig. 6D) was analyzed in normoxia and hypoxia exposed A549 EPOR WT and KO cells. 
EphB4 expression displays no differences in both, A549 EPOR WT and KO cells under 
normoxic and hypoxic conditions. In contrast, EFNB2 was induced during hypoxia in EPOR 
WT (2-fold) and KO cells (2-fold). Moreover, comparing EFNB2 expression levels between 
EPOR WT and KO cells indicates that the lack of EPOR increases the expression of EFNB2 
by 3 to 4-fold under both, normoxic and hypoxic conditions. If EFNB2 is and alternative 
ligand for EPOR in A549 cancer cells, the induction of EFNB2 in EPOR deficient cells might 
be a compensatory mechanism. 
To verify if EFNB2, with a size of 36 kDa is a potential candidate that mediates 
radioresistance via EPOR, centrifugal filtration with different filter sizes was performed. 
Centrifugal filtration removed all molecules smaller than 3 kDa, 30 kDa and 100 kDa from 
the normoxia and hypoxia preconditioned medium of A549 EPOR WT cells. Filtering 
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hypoxia-preconditioned medium with filter-sizes of 3 and 30 kDa, did not reduce the 
protective effect of hypoxia preconditioned medium (data not shown). Even after filtering 
preconditioned medium with a 100 kDa centrifugal filter (Fig. 6E), colony formation in A549 
EPOR WT but not KO cells treated with filtered medium was increased after 3 Gy irradiation. 
Since most of receptor ligands are smaller than 100 kDa we performed an extracellular vesicle 
centrifugation to isolate microvesicles out of normoxic and hypoxic WT PC medium and to 
analyze their role in hypoxia-induced radioresistance (Fig. 6F). However, using a simplified 
protocol to isolate these vesicles caused no protection of A549 WT cancer cells from 
irradiation. These preliminary data suggests that the factor released during hypoxia conferring 




Fig. 6 Possible cross interactions for EPO-EPOR signaling 
A,B,C,D: Semi-quantitative analysis of mRNA by SYBR Green real time PCR was used to analyze gene expression of A549 
WT and EPOR KO clones (X-axis). Cells were exposed to hypoxia (black bars; 1% O2) or remained in normoxia (white bars; 
21% O2) for 24 h, RNA was isolated and cDNA prepared. Target gene expression was normalized to β-Actin and is shown as 
fold changes (Y-axis) (delta-delta Ct method). Analyzed Genes are Prostaglandin E synthase (A) (PTGES), Major Vault 
Protein (MVP) (B), Ephrin receptor B4 (EphB4) (C) as well as Ephrin B2 (EFNB2) (D). E,F: Colony formation was 
analyzed after a single dose of radiation (3 Gy), via clonogenic assay. Data were normalized to non-irradiated control in % 
(Y-axis). Medium was preconditioned on WT cells for 24 h on confluent plates in either normoxic (21% O2; white bars) or 
hypoxic (1% O2; black bars) conditions. E: Preconditioned medium (PC) was filtered by 100 kDa centrifugal filtration to 
remove all substances smaller than 100 kDa. WT and EPOR KO cells were treated with filtered, preconditioned medium 24h 
before X-ray treatment (3 Gy). Filtered hypoxia preconditioned medium protects WT but not EPOR KO cells from radiation. 
F: PC medium was filtered to isolate microvesicles, and microvesicle pellet was then taken up in Medium and distributed on 
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cells 24h before X-ray treatment (3 Gy). A Students t-test was performed for statistics. (Mean ±SD; n=3-5; *p<0.05, 
**p<0.01, ***p<0.001) 
6 Discussion 
In this study, we showed that A549 lung cancer cells express EPOR and generated A549 EPO 
receptor knock out cells with CRISPR/Cas that were used together with previously generated 
A549 shRNA EPOR knock down cells to analyze the role of EPOR in chemo- and 
radioresistance. We demonstrate that hypoxia-inducible chemo- and radioresistance of EPOR 
expressing A549 cells disappears in cells with reduced or completely ablated EPOR 
expression levels. These data indicate that EPOR is indeed involved in resistance to chemo- 
and radiotherapy – especially under hypoxic conditions. However, neither rhEPO 
administration nor EPO overexpression protect A549 cells from chemo- and radiotherapy, 
whereas hypoxic-preconditioned medium is sufficient to protect these cells under normoxic 
conditions, suggesting that EPO is at least not the only factor required to protect A549 lung 
cancer cells from chemo- and radiotherapy.  
 
We and others [35] showed that A549 human lung cancer cells express EPOR similar to a 
large number of other human cancer cells [12, 24, 52]. Several studies report that EPOR is 
also expressed in different types of tumors in human cancer patients [53-55]. However, the 
clinical relevance and the underlying mechanisms are not yet fully understood [14, 26]. 
Recently, He et. al. showed that elevated EPO/EPOR protein levels in NSCLC patients 
correlated with poor survival [27]. A549 human lung cancer cells (and other cell lines) 
display radio- and chemotherapy resistance – especially under hypoxic conditions [56] [30] 
[31]. With the genetic ablation of EPOR expression using shRNA and CRISPR/Cas 
technology we showed that hypoxia-inducible resistance to radiation and Gemcitabine is 
mediated by EPOR, i.e. targeting EPOR results in cancer cells that remain susceptible to 
radiation or Gemcitabine even under hypoxic conditions. Similarly, previous studies reported 
a decreased radio- and chemoresistance in U87 EPOR silenced glioma cells [29], thus 
supporting our recent findings in A549 lung cancer cells. Interestingly, EPOR inhibition in 
U87 also seems to sensitize glioblastoma cells to irradiation and Temozolomide under 
normoxic conditions, associated with increased DNA Damage in shEPOR cells. Reduced 
DNA damage and increased DNA repair are well-studied mechanisms that account especially 
for radioresistance [47]. In contrast to U87 glioma cells, EPOR deficient A549 lung cancer 
cells are neither more susceptible to radiation under normoxic conditions nor was an 
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involvement of DNA damage and repair mechanism under normoxia and hypoxia observed. It 
has to be mentioned that time points and irradiation dosages between our study and Peres et 
al. [29] differed, which might explain different results. However, it seems to be more likely 
that A549 lung cancer cells utilize other mechanisms and pathways downstream of EPOR to 
mediate hypoxia-induced resistance to chemo- and radiotherapy – one of them might be a 
reduced level of apoptosis [57]. Consequently, it might be possible that tumors in human 
patients, that express EPOR, might involve different, tumor-specific pathways to protect 
cancer cells from therapeutic interventions.  
 
EPO is the ligand for the EPO receptor and has been reported to negatively influence clinical 
outcome of cancer patients [9, 58-60]. Thus, it seems obvious that EPOR mediated resistance 
to irradiation under hypoxia involves EPOR activation by EPO. Indeed, several studies report 
on increased proliferation in breast and lung cancer cells after rhEPO administration [61] [62]. 
In the present study, we showed that hypoxia-induced radioresistance requires the expression 
of EPOR. However, treating A549 cells with rhEPO instead of exposing them to hypoxia 
failed to protect them from irradiation. EPO overexpression, to test if these cells might only 
respond to endogenously produced but not recombinant EPO, had no protective effect either 
after irradiation. Similarly, Rheinbothe et. al., showed that the partial loss of EPOR in human 
breast cancer cell lines including MDA-MB-231 and MCF7 results in reduced cell 
proliferation, whereas the administration of rhEPO did not further increase cancer cell 
proliferation [63]. The interpretation of these data seems to be easy, suggesting that EPO 
might be not required for EPOR-dependent cancer cell resistance. However, two aspects show 
possible limitations and have to be considered: 
I) Many cells including A549 cancer cells require cell culture medium supplemented with 
fetal calf serum (FCS), which contains bovine EPO. Human and bovine EPO show a 
high similarity (79% analogic sequence via gene blast), suggesting that bovine EPO 
might be able to activate human EPOR. It is currently not known if bovine EPO can 
bind the human EPOR. However, it has been reported that U87 glioma and HT 100 
primary cervical cancer cells only respond to rhEPO when FCS was heat inactivated 
suggesting that bovine EPO indeed may activate human EPOR [56]. All experiments 
conducted in this study were performed with heat inactivated FCS, but it cannot be 
ruled out that, although heat inactivated, FCS might still contain biologically active 
bovine EPO. Given the high amount of FCS used in cell culture, the heat-inactivated 
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bovine FCS might be sufficient to fully activate EPOR, explaining the non-
responsiveness of A549 cells to EPO administration and overexpression. 
II) Exposure to hypoxia not only regulates the release of potentially cytoprotective factors 
but also intracellularly signaling pathways like apoptosis [64] and cell cycle[65]. 
Additionally, hypoxia might be required to upregulate expression and activation of 
EPOR[14]. However, A549 cells did not display altered EPOR mRNA gene expression 
when exposed to hypoxia. To analyze if A549 lung cancer cells require direct exposure 
to hypoxia to induce radioresistant processes, we utilized preconditioned (PC) medium 
of hypoxia exposed A549 wild type cells and showed that hypoxic PC medium is 
sufficient to protect EPOR-expressing but not EPOR-deficient A549 cells from 
irradiation under normoxic conditions. Of note, hypoxic PC medium of EPOR deficient 
A549 cells also protects EPOR-expressing but not EPOR-deficient A549 cells, 
suggesting that the released factor that mediates radioresistance in A549 wild type cells 
is regulated independently of EPOR.  
 
EPO has been shown to affect cells independent of the EPO Receptor [66], probably via the 
ephrin receptor B4 (EphB4) [51] . On the other hand EPO has been also shown to have no 
effect on proliferation in EPOR positive cells [63, 67]. Our data suggest that radioresistance 
under hypoxia requires EPOR but if EPO is required remains questionable, leading us to two 
hypotheses; first it is possible that bovine EPO in the FCS – although heat-inactivated – 
completely activates EPOR under both normoxic and hypoxic conditions and neither 
administration of rhEPO nor endogenous EPO expression is required to activate EPOR. To 
confer radioresistance the fully activated EPOR requires a second, hypoxia-inducible and 
secreted factor that binds to its receptor. Only the co-stimulation of both sufficiently induces 
radioresistance under hypoxia. A second possibility is that EPOR has an alternative ligand. In 
conclusion, our data indicate that a factor either replacing or in addition to EPO is involved in 





Fig. 7 Possible mechanisms for hypoxia-induced radioresistance 
Hypoxic A549 cells secret a so far unidentified factor (here named as factor X), independent of EPOR expression. The 
incubation with hypoxic preconditioned medium renders EPOR expressing cells resistant to radiotherapy, suggesting a 
paracrine pathway. Currently, two theories could explain this mechanism. Hypothesis 1: EPO is binding to its receptor 
EPOR, but a second stimulus (co-stimulation theory), here presented as Factor X, binds to its respective Receptor X is 
needed to cause hypoxia-induced radioresistance. Hypothesis 2: EPOR presenting cells develop hypoxia-induced resistance 
by Factor X binding to EPOR as an alternative ligand instead of EPO. 
 
 
Currently, no other ligand but EPO has been discovered to bind EPOR. However, it has been 
recently reported, that EPO alternatively binds to EphB4, besides its original ligand Ephrin 
B2 (EFNB2) [51]. Moreover, the authors demonstrated that EphB4 but not EPOR correlated 
with poor outcome of EPO treated cancer patients. Given that EPO indeed binds to EphB4 it 
might be also possible that EFNB2 is also able to bind EPOR to replace EPO as ligand. In 
fact, we observed that EFNB2 mRNA expression is induced in hypoxia-exposed cells. 
Moreover, cells lacking EPOR appeared to have a higher baseline expression of EFNB2 
suggesting that cells might try to compensate the loss of EPOR. It has further been proposed 
that there might be an EPOR-EPHB4 heterodimer or an EPOR-b(CR)-EPHB4 heterotrimer 
[68]. We found that EPHB4 is expressed in normoxia as well as hypoxia-exposed A549 cells 
suggesting that hypoxia-inducible EFNB2 might be indeed an alternative EPOR ligand or is at 
least required to confer radioresistance. In addition to that we analyzed mRNA expression of 
other factors that have been previously reported to enhance EPO signaling. For example, 
erythroid cells display enhanced colony formation after EPO administration, if Prostaglandin-
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E2  is used as a co-administered substance [49]. However, we observed no differential gene 
expression of Prostaglandin E Synthase (PTGES) expression in hypoxia-exposed cells. 
To reduce the number of potential, secreted factors that account for hypoxia-inducible 
radioresistance, centrifugal filter units with different pore sizes where used to narrow down 
the molecular weight of this factor. We observed that the protective factor remained in a 
fraction larger than 100 kDa, which would exclude EFNB2 with its size of ~56 kDa as a 
candidate. One candidate protein that has been reported to be associated with EPO/EPOR and 
its downstream signaling pathway JAK/STAT is the mayor vault protein (MVP) [48] [69], 
also known as resistant related protein (LRP) with a size of ~110 kDa. It seems to play a role 
for resistance to anti-cancer therapy [50] by clearing drugs from their subcellular targets 
through sequestration into exocytotic vesicles [70]. Although we observed no changes in 
DNA damage and repair in our model, MVP has been also shown to support DNA-repair as 
an intracellular transport protein or shuttling vector for DNA-repair related Proteins [71]. 
However, A549 cells did not respond with increased MVP mRNA expression levels during 
hypoxia, suggesting that it rather plays no role in EPOR-mediated and hypoxia-induced 
radioresistance.  
Since the majority of receptor binding ligands is smaller than 100 kDa, we further explored 
the possibility of extracellular vesicles instead of single proteins being involved in EPOR-
mediated radioresistance. Extracellular vesicles are larger than 100 kDa and divide into two 
groups of small endosomal-derived exosomes (diameter <100 nm) and membrane-derived 
microvesicles (> 100nm) [43]. Such vesicles have been reported to play critical roles in 
cancer progression, dissemination and therapy [72-74] and carry proteins, mRNA, microRNA 
and membrane bound receptors or other molecules [75, 76] that can be either taken up by 
target cells or directly interact with their target cells [76, 77]. Aforementioned EFNB2 with a 
molecular size of ~56 kDa has been shown to be present in such vesicles [78] and could 
protect A549 cells from radiation, if it is indeed associated to such vesicles that are larger than 
100 kDa. To analyze if microvesicles, released during hypoxia, are capable of mediating 
EPOR-dependent radioresistance, we performed a pilot experiment and showed that the 
microvesicles fraction, which we isolated (>100 kDa) did not protect A549 cells from 
irradiation. However, it has to be mentioned that conventional FCS, that is typically used in 
cell culture contains already a large amount of such vesicles [76] and our simplified isolation 
protocol of vesicles depended solely on medium centrifugation and may mask the protective 
effect. These experiments should and will be repeated with vesicle free FCS and isolation of 
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bioactive vesicles (microvesicles and exosomes) will be performed with optimized 




To ultimately identify the factor that mediates EPOR-dependent radioresistance, several 
experiments will be performed in the future: Improved isolation methods of extracellular 
vesicles and especially exosomes that are smaller than 100 nm will be applied, to test if 
vesicle secretion plays a role for the in hypoxia-induced resistance and if EFNB2, as a 
component of these vesicles, is involved in that mechanism. A second candidate to analyze is 
the stem cell factor (SCF), which also has been reported to be present in extracellular vesicles 
[79], as well as to exist in a membrane bound isoform, possibly leading to vesicular secretion 
[80]. It has been reported that SCF gene expression is induced under hypoxic conditions [81] 
and that blocking SCF is sufficient to inhibit cancer stem cells proliferation and survival 
promoted by chemotherapy in NSCLC [82] or leading to increased colony formation and 
migration [83]. In addition functional and compositional characterization of extracellular 
vesicles, human recombinant EFNB2 and SCF protein will be used, to analyze if their 
administration protects normoxic cells from radioresistance in an EPOR-dependent fashion. 
Moreover, it is essential to understand if EPOR-mediated radioresistance involves the 
classical EPO/EPOR/JAK2 pathway, which will be tested by utilizing AG490, a well 
established JAK2 inhibitor to target specifically the JAK2/STAT pathway [84, 85], and 




Our results show that EPOR may have indeed a clinical relevance for lung cancer, even 
though expressed to very low levels. Our current data imply that EPO administration to 
anemic cancer patients might be without effects for therapy resistance if EPOR in lung cancer 
cells binds an alternative ligand or if lung cancer cells with low EPOR expression levels are 
already saturated by endogenously produced EPO. If these hypotheses hold true, cancer-
specific targeting EPOR instead of restricting EPO administration could not only prevent 
potentially EPO induced cancer promotion but might be a possible anti cancer strategy to 
prevent therapy resistance especially under hypoxic conditions because tumor hypoxia often 
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causes therapy resistance in many different kinds of tumors [86]. However, before that it is 
important to fully decipher and understand the underlying mechanisms and the role of EPOR 
in cancer. At the current stage of research and in the light of the current manuscript (A549 
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